• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

How one OD encouraged glaucoma medication adherence

Optometry Times JournalJuly digital edition 2020
Volume 12
Issue 07

Education brought the patient and doctor to the same wavelength

Glaucoma treatment can, in some ways and in certain contexts, be seen as a bad joke.

Imagine this conversation: “Sir, you have signs of glaucoma. Your intraocular pressure (IOP) is 28 mm Hg in each eye. Your optic nerves demonstrate a little of what we call cupping. Think of it as the donut being eaten away from the donut hole rather than from the outer rim. Your visual field studies look pretty good, but one metric called the glaucoma hemifield test is flagged for each eye’s visual field. This test here, performed by a tomogram that delves into the tissues of the back of the eye, shows thinning of the nerve fibers that converge to form the optic nerve in each eye relative to people who don’t have glaucoma. I know you just came in for a copy of your contact lens prescription and have no symptoms, but here are drops that will probably give you transient redness, which I can assure you is not as bad as untreated glaucoma.”

Sometimes that can be a tough sale, especially with respect to the patient who “feels fine, so nothing could possibly be wrong.” My own primary care physician and I once commiserated over this very scenario. He said he encounters it frequently in patients with systemic hypertension and high cholesterol.

His experience is typical with males who come in for a physical examination and receive a diagnosis of 1 or both of these conditions, decide they feel fine, and subsequently show up down the road whenever they feel like it.

I told him this is analogous to glaucoma: the “silent killer” and the “silent blinder” going hand in hand. As with blood pressure, IOP must be high before symptoms emerge.

Case example

I have a patient with ocular hypertension whom I have been treating for several years and who fits into this category. This Black woman aged 57 years has a history of systemic hypertension, chronic obstructive pulmonary disease (COPD), and HIV. Her hypertension is controlled with an oral diuretic. Her COPD is controlled with an inhaled bronchodilator and oral steroids as needed. Her HIV is controlled with an oral antiretroviral medication, and her viral load is not detectable.

She has a family history of cataracts but no known family history of glaucoma. She is a low hyperope and presbyope and first presented to me because I gave a community talk about the importance of comprehensive eye examinations. (I should do more of that.)

When she first presented at my office, she complained of blur that was easily alleviated with a new pair of glasses. Her IOPs, however, were 32 mm Hg OD and 34 mm Hg OS.

Her optic nerves looked healthy with vertical cup-to-disc ratios of 0.3 in each eye, no notching in either eye, and healthy nerve fiber layers in each eye. I took dilated optic disc photographs and invited her back in a week for a glaucoma work-up. At that visit, which was in the morning as opposed to her first visit in the afternoon, her IOPs were 30 mm Hg in each eye. Pachymetry showed thin to average central corneal thicknesses for each eye, and gonioscopy showed angles open to the ciliary body with mild pigmentation in the trabecular meshwork and a flat iris approach in each quadrant for both eyes.

Her visual field study was clear, and her spectral domain optical coherence tomography (SD-OCT) study showed clear retinal nerve fiber layers but a trace amount of ganglion cell complex thinning in each eye.

Hypertension or glaucoma

I explained to the patient that her condition was ocular hypertension or very mild glaucoma but that, either way, her IOPs were high enough to treat. So, I prescribed a generic prostaglandin analog and invited her back in 6 weeks for an IOP check. She returned but told me that there was no way she was taking any drops because those that I prescribed made her eyes “light up like a Christmas tree.”

I had explained the known and common adverse effects (AEs) of topical prostaglandins. With that said, her eyes were very injected. Her IOPs were at target, however. My target was 21 mm Hg to 24 mm Hg for each eye. I explained that we could try another class of medications. She was adamant and said, “No. More. Drops.” I explained the options of laser procedures and minimally invasive surgical procedures and offered her a referral. She said there was a 0% chance of that happening.

A convincing treatment

I managed to convince the patient that the worst thing would be to leave her IOP untreated. Beta blockade was contraindicated due to her COPD. So, I gave her a sample of an alpha-2 agonist and managed to convince her to use it 3 times each day and come back in 3 weeks. I also asked her to call me any time if she experienced undesirable AEs.

The patient returned for her follow-up appointment and was happy. She reported good drop adherence and a desirable AE: Her eyes appeared brighter and whiter to her. Her IOP was 23 mm Hg in each eye, and her optic nerves, IOPs, and visual field studies have been stable for several years now. This patient took some convincing, but educating her at length eventually put us on the same wavelength.

Related Videos
Lorraine Provencher, MD, presenting slides
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Melissa Tawa, OD, FAAO
Deborah Ristvedt, DO, details CIME 2024 presentation on glaucoma management
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
Nate Lighthizer, OD, speaks on lasers in optometry at AAOpt 2023
© 2024 MJH Life Sciences

All rights reserved.